Gazing into the future – what will the next 100 years of diabetes innovation look like? A perspective from industry

ZOE CHOLEWA

Great leaps of understanding and improvement have been made in the past 100 years (Figure 1), but according to the 2019-2020 national diabetes audit, fewer than 15% of people with diabetes are able to achieve target glucose levels.[1]

Fortunately, a new standard of care emerged with real-time

Figure 2. Real-time CGM versus BGM reading profile.[2]

Simon-Kucher & Partners. HCP discussions Nov 2021

**Figure 1.** History of technology timeline.

If your glucose alerts and reading from the CGM system do not match symptoms or expectations, please use a blood glucose monitor to make diabetes treatment decisions

Figure 3. The Dexcom portfolio of real-time CGM systems

† For a list of compatible smart devices, please visit www.dexcom.com/compatibility. Smart device required to display readings on watch.
‡ CE2797.
§ Compatible insulin-delivery device sold separately.

Address for correspondence: Zoe Cholewa
Senior Medical Affairs Manager, UK, Ire & Benelux | Dexcom
Dexcom, Unit 2.12/14, Building 3, Watchmoor Park, Camberley, GU15 3YL, UK
E-mail: zoe.cholewa@dexcom.com

continuous glucose monitoring (rt-CGM) from Dexcom (Figure 2). Dexcom rt-CGM works continuously to measure glucose levels without intervention and helps to minimise guesswork derived from making diabetes treatment decisions based on a blood glucose meter (BGM) reading alone - with no fingerpricks or scanning.

NICE now recommends that people with T1DM are offered a choice of glucose sensor, including rt-CGM.[3,4] For people with insulin-treated T2DM, NICE now recommends that rt-CGM can be considered as an alternative to intermittent scanning.[5]

Dexcom is increasing access to rt-CGM for people with diabetes with a range of products (Figure 3).

Ultimately, the aim is to offer continuity and reliability for

Gazing into the future….

Key messages

- NICE now recommends that people with T1DM are offered a choice of glucose sensor, including rt-CGM.[3,4]
- For people with insulin-treated T2DM, NICE now recommends that rt-CGM can be considered as an alternative to intermittent scanning.[5]
- Dexcom is increasing access to rt-CGM for people with diabetes with a range of products, Dexcom ONE, Dexcom G6 and Dexcom G7.

people with diabetes while delivering clinical and quality-of-life outcomes with lower HbA$_{1c}$, decreased episodes of hypoglycaemia,[6] and more efficient clinic visits. The future is looking very exciting for diabetes care. Where will the next 100 years take us?

Conflict of interest None.
Funding None.

References

1. Type 1 diabetes technology: a consensus guideline. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2019-20-type-1-diabetes.
2. Dexcom. Simon-Kucher & Partners. HCP discussions, November 2021.
3. Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. https://www.nice.org.uk/guidance/ng17.
4. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline [NG18]. https://www.nice.org.uk/guidance/ng18.
5. Type 2 diabetes in adults: management. NICE guideline [NG28]. https://www.nice.org.uk/guidance/ng28.
6. Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre randomised controlled trial. *Lancet* 2021;**397**(10291):2275–2283. https://doi.org/10.1016/S0140-6736(21)00789-3